Treatment with any other investigational agent within  weeks (or within five half-lives of the investigational product, whichever is shorter) prior to cycle , day  (minimum of  week between prior therapy and study enrollment); patients must be >=  weeks since any investigational agent administered as part of a phase  study (also referred to as an early phase I study or pre-phase I study where a sub-therapeutic dose of drug is administered) at the coordinating center PIs discretion, and should have recovered to eligibility levels from any toxicities
Participants who are currently receiving any other investigational agents; treatment with an investigational agent within  weeks prior to planned initiation of study therapy is allowed provided that any drug-related toxicity has completely resolved
Treatment with another investigational agent under the following conditions:
Concomitant treatment with another investigational agent while participating this trial.
Treatment with an investigational agent within  weeks of the first dose of treatment
SAFETY RUN-IN: Patients participating in another trial of an investigational agent within  weeks of the first dose of the study
Known or suspected allergy to the investigational agent or any agent given in association with this trial.
Other investigational agent(s) within  days prior starting to study treatment.
Exposure to any other investigational agent at any time within  weeks before the first dose of study treatment
Treatment with any investigational agent within  weeks prior to baseline
Prior participant in another protocol using an investigational agent within  half-lives of the investigational agent
Participants is taking another investigational agent
Plans to initiate treatment with an investigational agent during the study
Have taken an investigational agent within  days of visit 
Use of any standard chemotherapy or other investigational agent(s) within  week of study enrollment
Patients receiving investigational agent within  days of enrollment. However, the principal investigator (PI) may approve prior use of an investigational agent if the agent is not expected to interfere with the safety or the efficacy of alpha--antitrypsin.
Treatment with any investigational agent within  days of first administration of study treatment is not permitted
Patient is currently using, or planning to use another investigational agent
Patients who have been treated with an investigational agent within  days prior to the first dose of study drug.
Use of an investigational agent within  weeks of enrollment (day )
Use of other investigational agent for prostate cancer
Known or suspected allergy to the investigational agent or any agent given in association with this trial
Subjects who anticipate use of other investigational or non-investigational agents for the treatment of MDS during the study period, aside from a stable dose of erythropoietin stimulating agent started > weeks prior to screening for this study.
Treatment with any investigational agent within  days of first administration of study treatment.
Administration of any investigational agent within  weeks prior to initiating study treatment
Cytotoxic therapy or investigational agent use within  days
Patients participating in another trial of an investigational agent within  weeks of the st dose of the study
Treatment with a prior investigational agent within  days of first dose of investigational medication
Subject has received an investigational therapeutic agent for prostate cancer within  weeks prior to the administration of I-MIP-
Any previous treatment with a DDR agent, including any of the investigational agents
An interval of >=  weeks after the last administration of any investigational agent or any other treatment prior to first dose of pembrolizumab
Administration of any investigational agent within  weeks prior to initiating study treatment
Concurrent treatment with any other investigational agent
Is currently participating in a study of an investigational agent and received an investigational agent within  weeks of the first dose of treatment
Treatment with other investigational agent(s) within  days of planned lymphodepletion
Treatment with any other investigational agent within  weeks prior to the first dose of MEDI and tremelimumab
Any investigational agent within  weeks prior to initiating study treatment
Any investigational agent within  weeks prior to initiating study treatment
Any investigational agent within  weeks of study treatment initiation
Patients may not receive concurrent treatment with other investigational or commercial agent(s) for treatment of their breast cancer
Use of any investigational agent within  weeks prior to study entry.
Patients receiving any other standard or investigational treatment for their cancer, or any other investigational agent for any indication, within the past  weeks prior to initiation of treatment with study drugs
Treatment with an investigational anti-cancer agent within  weeks prior to enrollment into the study
Patients receiving any other standard or investigational treatment for their cancer, or any other investigational agent for any indication, within the past  weeks prior to initiation of treatment with study drugs
Research participant must be at least  weeks out from having received the last dose of investigational agent
Use of any investigational agent within  weeks prior to the Baseline Visit.
Patients should not have received an investigational agent for at least  weeks prior to the first study drug dose
The use of any investigational agent in the month before enrollment into the study
Investigational agent within  weeks of first dose of study treatment
Patients may not have used any investigational agent within  weeks prior to enrollment into the study
While on this study, patients may not be treated with any other investigational agent for any purpose until relapse or progression
Known history of hepatitis B or C as these patients may be at risk of disease reactivation when treated with the chemotherapy and/or the investigational agent
Investigational agent: >=  days must have elapsed from treatment with a different investigational agent
Administration of any unlicensed or investigational agent within  weeks of entry to the study
No prior investigational agent in the  weeks prior to initiation of therapy
Use of investigational agent within  days of signing informed consent
Use of any investigational agent within  days of the first radiation dose
Use of investigational agent within last  days
Use of any investigational agent within  weeks prior to study entry.
Use of an investigational agent within  weeks of enrollment
Treatment with any other investigational agent within  days prior to enrolment.
 weeks from any investigational agent
Exposure to any investigational agent within  weeks prior to initiation of study treatment.
Less than  weeks since use of another investigational agent
Treatment with any investigational agent within  weeks prior to baseline
Treatment with any investigational agent within  weeks prior baseline
Patients who have received treatment with any other investigational agent within  weeks before initiation of study treatment
Any antineoplastic agent for the primary malignancy (standard or investigational) without delayed toxicity within  weeks prior to first administration of IMP and during study with exceptions
Treatment with any other investigational anti-leukemia agent
Any investigational agent(s) within  weeks prior to entry
Concurrent administration of any other investigational agent considered to have potential efficacy in the treatment of breast cancer
Any investigational agent within  weeks prior to initiating study treatment
TREATMENT: Patients who have had prior treatment with any of the other investigational agents or combinations on this protocol are eligible but will not receive the same investigational agent (everolimus or trametinib) or combination (AZD/combination or veliparib/temozolomide); instead, patients will receive an investigational agent or combination prospectively identified to work on a different target in their tumors mutation/aberrant pathway
Concurrent treatment with an investigational agent
Subjects having received any other investigational agents within  weeks prior to the\n             first study drug administration and have not recovered completely (to AEs <  Grade )\n             from the side effects of the earlier investigational agent
Patients with a history of prior therapy with another investigational agent within  weeks of the first planned dose of PF-
Concurrent treatment with an investigational agent other than the investigational agent(s) used in this study OR treatment within  weeks of study entry with any investigational agent(s) or device(s)
Any intravesicular or other chemotherapy treatment within  weeks or any investigational agent within  weeks prior to the initial dose of study drug.
?  days elapsed from the administration of any investigational agent
Use of any investigational agent within the  weeks preceding enrollment
Any investigational agent within  weeks of Day  of trial drug treatment
First day of dosing with tesevatinib is less than  weeks from treatment with another investigational agent
No investigational agent within  weeks prior to first dose of study drug.
Have been treated with an investigational agent within  weeks prior to the first day of IP administration.
Administration of any investigational agent within  days of first dose of study drug
Any investigational agent within the previous  days.
Treatment with radiotherapy, any chemotherapeutic agent, systemic steroids used as an anti-neoplastic agent, or any other investigational anti-cancer agent within  weeks prior to Cycle , Day 
Treatment with any other investigational agent
Previously received treatment with RGX- or another investigational agent that is a known LXR agonist.
Treatment with an investigational agent within  weeks of starting treatment.
Use of an investigational agent or an investigational device within  days before administration of first dose of NKTR-.
Use of investigational agents within  weeks prior to study enrollment (within  weeks if the treatment was with a long-acting agent such as a monoclonal antibody).
Administration of any investigational agent within  days of first dose of study drug
Treatment with any investigational agent within three weeks prior to first dose in this study
Treatment with any investigational agent within  days of first administration of study treatment
Treatment with any investigational agent within three weeks prior to first dose in this study
Taking an investigational agent within  weeks of initiation of everolimus
Received any chemotherapeutic or targeted agent (approved or investigational) for NSCLC within  weeks of initiation of pacritinib (with the exception of erlotinib)
Known or suspected allergy to the investigational agent or any agent given in association with this trial
At least  weeks must have elapsed from the use of any other investigational agent prior to starting study drug
Subjects who received an investigational agent < days prior to their first day of study drug administration. In addition, the first dose of AG- should not occur before a period ? half-lives of the investigational agent has elapsed.
Use of an investigational agent within  weeks of enrollment (day  visit)
Use of any investigational agent within  weeks prior to study entry.
Subjects who received a small molecule investigational agent < days prior to their first day of study drug administration. In addition, the first dose of AG- should not occur before a period ? half-lives of the investigational agent has elapsed.
Patients who have participated in a window study (treatment with an investigational agent prior to surgery for =<  weeks) are eligible; patients must have discontinued the investigational agent at least  days before participation
Treatment with an investigational agent within  weeks before dosing
Treatment with any investigational agent within  days of first administration of study treatment
Use of an investigational agent, including an investigational anti-cancer agent, within  days prior to the first dose of study drug
No use of an investigational agent within  weeks of starting ECP
Current active treatment with an investigational agent
complete abstinence from intercourse from  weeks prior to administration of the st dose of study agent and  months after the last dose of study agent; or
Any investigational agent within  weeks of first dose of study treatment
Treatment with a an investigational agent within  days prior to the first dose of dasatinib/ATRA or planning to receive an investigational agent during the study
An investigational agent within the past  days
Current use of an investigational agent
Any investigational agent, other than NEOD, within  weeks
Use of an investigational therapeutic agent with  weeks of enrollment
Treatment with an investigational agent within  days prior to the first dose of SNX? or planning to receive an investigational agent during the study.
Use of an investigational agent within  weeks of Day  visit.
Other investigational agent within  weeks prior to initiation of study therapy
Use of any investigational agent within  days prior to Baseline.
Concurrent treatment or treatment within  weeks of study entry with any other investigational agent or chemotherapy.
Concurrent treatment or treatment within  weeks of study entry with any other investigational agent or chemotherapy.
Patients receiving any other standard or investigational treatment for their cancer, or any other investigational agent for any indication, within the past  weeks prior to initiation of treatment with study drugs
Known or suspected allergy to the investigational agent or any agent given in association with this trial.
Treatment with any investigational agent within  weeks prior to first dose in this study.
Treatment with another investigational agent under the following conditions:
Concomitant treatment with another investigational agent while participating in this trial.
Current treatment with another investigational agent.
Use of any other investigational agent within  days before day .
More than  weeks from any investigational agent.
Use of any investigational agent within the last  days
Treatment with an unapproved, investigational agent within  days of the first dose of study drug
Concurrent treatment with an investigational agent
Treatment with any investigational agent <= weeks prior to first dose of study treatment
Received an investigational agent < days prior to their first day of study drug administration. In addition, the first dose of AG- should not occur before a period ? half-lives of the investigational agent has elapsed
Use of an investigational therapeutic agent within  days
Subject may not receive another investigational agent.
Must be  days from the administration of any investigational agent or prior cytotoxic therapy with the following exceptions:
Use of an investigational agent within the past  days
Use of any investigational agent within  days prior to start of CA-
Patients may not have received an investigational agent within  weeks of starting this trial
Donor must not be currently enrolled on another investigational agent study.
Received treatment with an investigational agent within  weeks of study entry, or is actively participating in another interventional clinical study.
Any other investigational agent within  days of study entry
Any antineoplastic agent (standard or investigational) within  weeks prior to starting trial treatment
Received an antineoplastic therapy or investigational agent after treatment with talazoparib in the originating protocol.
 days from the administration of any investigational agent
Systemic therapy or investigational agent administered <  days prior to treatment with nintedanib
Prior treatment with an agent targeting the exportin
Subjects who have received treatment with an investigational agent within  days of the projected first administration of Investigational Product (Day )
Use of investigational agent within  days of study entry
Patient is using or plans to use an investigational agent for the prevention or treatment of VOD.
Concurrent treatment with other investigational agent
Has received an investigational study agent within the previous  days, or is currently participating in or scheduled to participate in any other clinical study with an investigational agent during the -week study period
Exposure to any investigational agent (defined as any agent not approved by the Food and Drug Administration [FDA]) within  days prior to the Screening Visit
Planned treatment with agent targeting PIK/mTOR pathway (either standard of care or investigational agent)
Subjects must not receive concurrent or prior use of an immunosuppressive agent within  days of the first dose of investigational agent, with the following exceptions and notes:
Subjects must not have received another investigational agent within the shorter of  weeks or  half-lives before the first dose of investigational agent.
use of any investigational drug within  weeks of dosing (unless a longer time period is required by local regulations or the investigational agent)
Use of an investigational agent within  weeks of enrollment
No investigational agent within  weeks prior to first dose of study drug